These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

667 related articles for article (PubMed ID: 23380348)

  • 21. Corticomotoneuronal integrity and adaptation in spinal muscular atrophy.
    Farrar MA; Vucic S; Johnston HM; Kiernan MC
    Arch Neurol; 2012 Apr; 69(4):467-73. PubMed ID: 22491191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Performance-based or self-report measures of physical function: which should be used in clinical trials of hip fracture patients?
    Latham NK; Mehta V; Nguyen AM; Jette AM; Olarsch S; Papanicolaou D; Chandler J
    Arch Phys Med Rehabil; 2008 Nov; 89(11):2146-55. PubMed ID: 18996244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical, electrophysiological and molecular study of 26 chilean patients with spinal muscular atrophy].
    Castiglioni C; Levicán J; Rodillo E; Garmendia MA; Díaz A; Pizarro L; Contreras L
    Rev Med Chil; 2011 Feb; 139(2):197-204. PubMed ID: 21773657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A long-term prospective study of the natural course of sporadic adult-onset lower motor neuron syndromes.
    Van den Berg-Vos RM; Visser J; Kalmijn S; Fischer K; de Visser M; de Jong V; de Haan RJ; Franssen H; Wokke JH; Van den Berg LH
    Arch Neurol; 2009 Jun; 66(6):751-7. PubMed ID: 19506135
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reliability and responsiveness of the gross motor function measure-88 in children with cerebral palsy.
    Ko J; Kim M
    Phys Ther; 2013 Mar; 93(3):393-400. PubMed ID: 23139425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Motor unit loss estimation by the multipoint incremental MUNE method in children with spinal muscular atrophy--a preliminary study.
    Gawel M; Kostera-Pruszczyk A; Lusakowska A; Jedrzejowska M; Ryniewicz B; Lipowska M; Gawel D; Kaminska A
    Neuromuscul Disord; 2015 Mar; 25(3):216-21. PubMed ID: 25500012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Performance of the timed "up & go" test in spinal muscular atrophy.
    Dunaway S; Montes J; Garber CE; Carr B; Kramer SS; Kamil-Rosenberg S; Strauss N; Sproule D; De Vivo DC
    Muscle Nerve; 2014 Aug; 50(2):273-7. PubMed ID: 24375426
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Criterion validity of the spatial exploration test of upper limb mobility to evaluate the active horizontal workspace of children with spinal muscular atrophy.
    Pruvost S; Gomez Garcia de la Banda M; Quijano Roy S; Izedaren F; Roche N; Pouplin S
    Disabil Rehabil; 2024 Feb; 46(3):575-580. PubMed ID: 36650958
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial.
    Bertini E; Dessaud E; Mercuri E; Muntoni F; Kirschner J; Reid C; Lusakowska A; Comi GP; Cuisset JM; Abitbol JL; Scherrer B; Ducray PS; Buchbjerg J; Vianna E; van der Pol WL; Vuillerot C; Blaettler T; Fontoura P;
    Lancet Neurol; 2017 Jul; 16(7):513-522. PubMed ID: 28460889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of hydroxyurea in spinal muscular atrophy cells and patients.
    Liang WC; Yuo CY; Chang JG; Chen YC; Chang YF; Wang HY; Ju YH; Chiou SS; Jong YJ
    J Neurol Sci; 2008 May; 268(1-2):87-94. PubMed ID: 18166199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative muscle MRI: A powerful surrogate outcome measure in Duchenne muscular dystrophy.
    Bonati U; Hafner P; Schädelin S; Schmid M; Naduvilekoot Devasia A; Schroeder J; Zuesli S; Pohlman U; Neuhaus C; Klein A; Sinnreich M; Haas T; Gloor M; Bieri O; Fischmann A; Fischer D
    Neuromuscul Disord; 2015 Sep; 25(9):679-85. PubMed ID: 26096788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Six-Minute Walk Test demonstrates motor fatigue in spinal muscular atrophy.
    Montes J; McDermott MP; Martens WB; Dunaway S; Glanzman AM; Riley S; Quigley J; Montgomery MJ; Sproule D; Tawil R; Chung WK; Darras BT; De Vivo DC; Kaufmann P; Finkel RS;
    Neurology; 2010 Mar; 74(10):833-8. PubMed ID: 20211907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular genetics of spinal muscular atrophy: contribution of the NAIP gene to clinical severity.
    Akutsu T; Nishio H; Sumino K; Takeshima Y; Tsuneishi S; Wada H; Takada S; Matsuo M; Nakamura H
    Kobe J Med Sci; 2002 Apr; 48(1-2):25-31. PubMed ID: 11912351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mathematical Disease Progression Modeling in Type 2/3 Spinal Muscular Atrophy.
    Jacqmin P; Gieschke R; Delor I; Snoeck E; Vianna E; Vuillerot C; Sanwald Ducray P
    Muscle Nerve; 2018 Oct; 58(4):528-535. PubMed ID: 29938801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multidisciplinary physical rehabilitation program of individuals with spinal muscular atrophy in an inclusive school setting.
    Ahmed F; Islam A; Akter S; Al Zubayer MA; Mahmud MN; Yeasmin H; Mawa Z
    J Pediatr Rehabil Med; 2024; 17(2):247-252. PubMed ID: 38007681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy.
    Riessland M; Ackermann B; Förster A; Jakubik M; Hauke J; Garbes L; Fritzsche I; Mende Y; Blumcke I; Hahnen E; Wirth B
    Hum Mol Genet; 2010 Apr; 19(8):1492-506. PubMed ID: 20097677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natural history of Type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study.
    Annoussamy M; Seferian AM; Daron A; Péréon Y; Cances C; Vuillerot C; De Waele L; Laugel V; Schara U; Gidaro T; Lilien C; Hogrel JY; Carlier P; Fournier E; Lowes L; Gorni K; Ly-Le Moal M; Hellbach N; Seabrook T; Czech C; Hermosilla R; Servais L;
    Ann Clin Transl Neurol; 2021 Feb; 8(2):359-373. PubMed ID: 33369268
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and validation of a motor function classification in patients with neuromuscular disease: the NM-score.
    Vuillerot C; Rippert P; Roche S; Bérard C; Margirier F; de Lattre C; Poirot I; Berruyer A; Tiffreau V; Fournier-Mehouas M; Bouhour F; Urtizberea JA; Renders A; Ecochard R;
    Ann Phys Rehabil Med; 2013 Dec; 56(9-10):673-86. PubMed ID: 24231198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reliability and validity of outcome measures of in-hospital and at-home visits in a randomized, double-blind, placebo-controlled trial for spinal muscular atrophy.
    Chen TH; Yang YH; Mai HH; Liang WC; Wu YC; Wang HY; Jong YJ
    J Child Neurol; 2014 Dec; 29(12):1680-4. PubMed ID: 24163397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hip Displacement in Spinal Muscular Atrophy: The Influences of Genetic Severity, Functional Level, and Disease-modifying Treatments.
    Ulusaloglu AC; Asma A; Shrader MW; Scavina MT; Mackenzie WG; Erb A; Howard JJ
    J Pediatr Orthop; 2024 Mar; 44(3):e226-e231. PubMed ID: 38073182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.